Concerning treatments, the drug ATX-MS-1467, a four-peptides mixture of human MBP, showed interesting potential as immunomodulant, in part through IL-10 modulation, as reported in preclinical studies on EAE and in trials on MS patients [188, 189]. This evidence concerns the gene IL10 and myeloid sarcoma.